Literature DB >> 22297876

Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital.

Mariana Ribeiro Queiroz1, Hsin Fen Chien, Egberto Reis Barbosa.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate quality of life (QoL) in a Brazilian population of individuals with cervical dystonia (CD) without effect of botulinum toxin (BTx) or with only residual effect of BTx, and identify possible physical and social aspects that affect their QoL.
METHOD: Sixty five out of sixty seven consecutive patients with CD were assessed with two instruments: Short-form Health Survey with 36 questions (SF-36) and Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).
RESULTS: Severity of CD (TWSTRS) correlated moderately with two SF-36 subscale: role-physical (r= -0.42) and body pain (r= -0.43). Women also scored worse in two subscale of SF-36: vitality (p<0.05) and mental-health (p<0.005).
CONCLUSION: Severity of CD and gender (female) were the main factors related to a worse QoL perception. These findings may help health professionals to predict which characteristics could lead to worse QoL, and therefore, better target their interventions to lessen the burden caused by CD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22297876     DOI: 10.1590/s0004-282x2011000700010

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  7 in total

1.  Physical therapy program for cervical dystonia: a study of 20 cases.

Authors:  Mariana Araujo Ribeiro Queiroz; Hsin Fen Chien; Flávio Augusto Sekeff-Sallem; Egberto Reis Barbosa
Journal:  Funct Neurol       Date:  2012 Jul-Sep

2.  Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives.

Authors:  Dursun Ceylan; Sevda Erer; Mehmet Zarifoğlu; Nevin Türkeş; Güven Özkaya
Journal:  Neurol Sci       Date:  2019-01-18       Impact factor: 3.307

3.  Health-Related Quality of Life in Cervical Dystonia Using EQ-5D-5L: A Large Cross-Sectional Study in China.

Authors:  Yan Liang; Junyu Lin; Yanbing Hou; Lingyu Zhang; Ruwei Ou; Chunyu Li; Qianqian Wei; Bei Cao; Kuncheng Liu; Zheng Jiang; Tianmi Yang; Jing Yang; Meng Zhang; Simin Kang; Yi Xiao; Qirui Jiang; Jing Yang; Wei Song; Xueping Chen; Bi Zhao; Ying Wu; Huifang Shang
Journal:  Front Neurol       Date:  2022-06-23       Impact factor: 4.086

4.  Clinimetric testing of the comprehensive cervical dystonia rating scale.

Authors:  Cynthia L Comella; Joel S Perlmutter; Hyder A Jinnah; Tracy A Waliczek; Ami R Rosen; Wendy R Galpern; Charles A Adler; Richard L Barbano; Stewart A Factor; Christopher G Goetz; Joseph Jankovic; Stephen G Reich; Ramon L Rodriguez; William L Severt; Mateusz Zurowski; Susan H Fox; Glenn T Stebbins
Journal:  Mov Disord       Date:  2016-03-12       Impact factor: 10.338

5.  A retrospective study to assess resource utilization in patients with cervical dystonia in the United Kingdom.

Authors:  Mireia Raluy-Callado; Sylvie Gabriel; Jérôme Dinet; Meng Wang; Radek Wasiak
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-09       Impact factor: 2.570

6.  Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients.

Authors:  Priya Jagota; Lalita Kaewwilai; Nonglak Boonrod; Surat Singmaneesakulchai; Kamolwan Boonpang; Jirada Sringean; Onanong Jitkritsadakul; Sitthi Petchrutchatachart
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-08-04

7.  Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.

Authors:  Hsin Fen Chien; Ana Lucia Zuma de Rosso; André Sobierajski Dos Santos; Carlos Roberto de Mello Rieder; Debora Palma Maia; Delson José da Silva; Marcio da Cunha Andrade; Marcus Vinicius Della Coletta; Maria do Desterro Leiros da Costa; Nasser Allam; Roberto César Pereira do Prado; Vanderci Borges; Vitor Tumas; Wagner de Goes Horta
Journal:  eNeurologicalSci       Date:  2016-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.